New Drug for Multiple Myeloma Granted Orphan Status in Mexico

A new therapeutic approach for the treatment of multiple myeloma has been recognized in Mexico, receiving orphan drug status from the Federal Commission for the Protection against Health Risks (COFEPRIS). This represents a significant advance in addressing this complex hematological disease. The recognition was granted to belantamab mafodotin, developed by GSK, as an option for adult patients with relapsed or refractory multiple myeloma who have exhausted previous treatments, expanding the therapeutic alternatives available in the country. Sigfrido Rangel, medical director of GSK Mexico, stated that the company's objective is to generate new therapeutic alternatives for patients who have exhausted conventional options. He indicated that the research work aims to anticipate the evolution of complex diseases such as multiple myeloma, contributing to improving access to more effective treatments. The recognition of belantamab mafodotin as an orphan drug is a relevant step to strengthen the care of low-prevalence diseases and to expand therapeutic options in hematology-oncology. This advance is framed in the need to reduce gaps in timely diagnosis, access to treatment, and therapeutic continuity, key elements to improve clinical outcomes in patients with multiple myeloma. Multiple myeloma is a blood cancer that originates in the plasma cells of the bone marrow, responsible for antibody production. Its progression can lead to bone weakening, kidney damage, and susceptibility to infections, in addition to symptoms such as persistent pain, fatigue, and fractures from minimal effort. In Mexico, this disease affects more than 2,300 people annually and causes over 1,500 deaths, reflecting its impact on public health. Although it is usually diagnosed in older people—with an average age close to 70—recent data in the country places the diagnosis age around 59 years, showing a relevant clinical pattern. Additionally, it is associated with a greater risk of osteoporosis and anemia, and when the diagnosis occurs in advanced stages, the probability of serious complications and progression-free survival increases. Despite the existence of treatments such as bone marrow transplantation, only about 30% of patients have access to a second-line therapy, which shows gaps in access and continuity of treatment. Targeted therapy: an innovative mechanism of action Belantamab mafodotin is an antibody-drug conjugate directed against the B-cell maturation antigen (BCMA), present in multiple myeloma cells. Its mechanism allows the antibody to identify malignant cells, bind to them, and release a cytotoxic agent directly into their interior, causing their destruction. This approach represents a strategy of targeted medicine, aimed at improving the precision of treatment and reducing the impact on healthy cells. Clinical evidence: significant risk reduction Results from Phase III clinical studies showed significant benefits in the course of the disease. The combination of belantamab mafodotin with bortezomib and dexamethasone showed a 59% reduction in the risk of progression or death, with a median progression-free survival of 36.6 months, compared to the 13.4 months observed with standard treatment. In another trial, its combination with pomalidomide and dexamethasone achieved a 48% reduction in the risk of progression or death, reaching 32.6 months of progression-free survival, compared to the 12.5 months of the conventional regimen. These results position this therapy as an effective alternative for patients who have stopped responding to previous treatments, including those based on lenalidomide.